(Institución)
 
 

Docu-menta > Investigación Básica > Artículos de Investigación Básica >

Por favor, use este identificador para citar o enlazar este ítem: http://documenta.ciemat.es/handle/123456789/2352

Título : Preclinical studies of efficacy thresholds and tolerability of a clinically ready lentiviral vector for pyruvate kinase deficiency treatment
Autor : Navarro, Susana
Quintana-Bustamante, Óscar
Sánchez-Domínguez, Rebeca
López-Manzaneda, Sergio
Ojeda-Pérez, Isabel
García-Torralba, Aida
Alberquilla, Omaira
Law, Kenneth
Beard, Brian C
Bastone, Antonella
Rothe, Michael
Villanueva, Mariela
Ramírez, Juan Carlos
Fañanas-Baquero, Sara
Nieto-Romero, Virginia
Molinos-Vicente, Andrea
Gutiérrez, Sonia
Nicoletti, Eileen
García-Bravo, María
Bueren, Juan Antonio
Schwartz, Jonathan D
Segovia, José Carlos
Fecha de publicación : 29-jul-2021
Editorial : Molecular Therapy:Methods & Clinical Development
Citación : Navarro S, Quintana-Bustamante O, Sanchez-Dominguez R, Lopez-Manzaneda S, Ojeda-Perez I, Garcia-Torralba A, Alberquilla O, Law K, Beard BC, Bastone A, Rothe M, Villanueva M, Ramirez JC, Fañanas-Baquero S, Nieto-Romero V, Molinos-Vicente A, Gutierrez S, Nicoletti E, García-Bravo M, Bueren JA, Schwartz JD, Segovia JC. Preclinical studies of efficacy thresholds and tolerability of a clinically ready lentiviral vector for pyruvate kinase deficiency treatment. Mol Ther Methods Clin Dev. 2021 Jul 29;22:350-359. doi: 10.1016/j.omtm.2021.07.006. PMID: 34514027; PMCID: PMC8408550.
Resumen : Pyruvate kinase deficiency (PKD) is a rare autosomal recessive disorder caused by mutations in the PKLR gene. PKD is characterized by non-spherocytic hemolytic anemia of variable severity and may be fatal in some cases during early childhood. Although not considered the standard of care, allogeneic stem cell transplantation has been shown as a potentially curative treatment, limited by donor availability, toxicity, and incomplete engraftment. Preclinical studies were conducted to define conditions to enable consistent therapeutic reversal, which were based on our previous data on lentiviral gene therapy for PKD. Improvement of erythroid parameters was identified by the presence of 20%–30% healthy donor cells. A minimum vector copy number (VCN) of 0.2 0.3 was required to correct PKD when corrected cells were transplanted in a mouse model for PKD. Biodistribution and pharmacokinetics studies, with the aim of conducting a global gene therapy clinical trial for PKD patients (RP-L301-0119), demonstrated that genetically corrected cells do not confer additional side effects. Moreover, a clinically compatible transduction protocol with mobilized peripheral blood CD34+ cells was optimized, thus facilitating the efficient transduction on human cells capable of repopulating the hematopoiesis of immunodeficient mice. We established conditions for a curative lentiviral vector gene therapy protocol for PKD.
URI : http://documenta.ciemat.es/handle/123456789/2352
Aparece en las colecciones: Artículos de Investigación Básica

Ficheros en este ítem:

Fichero Descripción Tamaño Formato
23. Navarro- MOL THERAPY MCD 2021.pdf1.32 MBAdobe PDFVisualizar/Abrir
View Statistics

Los ítems de Docu-menta están protegidos por una Licencia Creative Commons, con derechos reservados.

 

Información y consultas: documenta@ciemat.es | Documento legal